NCT04167618 - 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

August 11, 2022

Study Completion Date

August 11, 2022

Conditions

Medulloblastoma, Childhood

Interventions

DRUG

177Lu-DTPA-omburtamab

Biological, radiolabeled DPTA-omburtamab

Trial Locations (10)

Rigshospitalet, Børneonkologisk afsnit, Copenhagen

Memorial Sloan Kettering Cancer Center, New York

Mayo Clinic, Rochester

M.D. Anderson Cancer Center, Houston

Doernbecher Children's Hospital, Portland

Princess Máxima, Utrecht

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Sant Joan de Deu de Barcelona, Barcelona

The Royal Marsden Hospital, London

Great North Children's Hospital, Newcastle